// App-Quantinova.ai

3517 : Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.

Researchers

Presenter

  • Elisa Fontana

Principal Investigators

  • Alberto F. Sobrero

  • Timothy Iveson

  • Anthony Frank Shields

  • Julien Taieb

  • Takayuki Yoshino

  • Ioannis Souglakos

  • Elizabeth Catherine Smyth

  • Florian Lordick

  • Markus H. Moehler

  • Andrea Harkin

  • Roberto Labianca

  • Jeffrey A. Meyerhardt

  • Thierry Andre

  • Takeharu Yamanaka

  • Ioannis Boukovinas

  • Axel Grothey

  • Irit Ben-Aharon

  • Qian Shi

Medical Centers

  • Sarah Cannon Research Institute, London, United Kingdom

  • NCRI, London, United Kingdom

  • Mayo Clinic, Rochester, MN, IRCCS Ospedale Policlinico San Martino, Genoa, Italy

  • University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

  • Karmanos Cancer Institute, Wayne State University, Detroit, MI, Hôpital Européen Georges Pompidou, Paris, France

  • National Cancer Center, EPOC, Chiba, Japan

  • Department of Medical Oncology, University Hospital of Heraklion, Heraklion, Crete, Greece

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • University Cancer Center Leipzig, Leipzig, Germany

  • University Medical Centre of Mannheim, First Department of Internal Medicine, Mannheim, Germany

  • Glasgow, United Kingdom

  • Cancer Center, ASST Papa Giovanni XXIII, Bergamo, Italy

  • Department of Medical Oncology, Dana-Farber Cancer Institute/Partners Cancer Care, Boston, MA

  • Sorbonne University, Hôpital Saint-Antoine,Paris,France

  • Department of Biostatistics Yokohama City University School of Medicine, Yokohama, Japan

  • Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece

  • Division of Medical Oncology, Mayo Clinic, Rochester, MN, Division of Oncology, Rambam Health Care Center, Haifa, Israel

Locations

  • United Kingdom

  • Italy

  • France

  • Japan

  • Greece

  • Germany

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

  • Solid malignancies

Biomarkers

  • Transthyretin

Drug/Treatment

  • Oxaliplatin

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT00749450

  • NCT00646607

  • NCT01150045

  • NCT00958737

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved